Drug Profile
Research programme: HIV-RNase H inhibitors - Astex Pharmaceuticals
Latest Information Update: 19 Apr 2012
Price :
$50
*
At a glance
- Originator Astex Therapeutics
- Developer Astex Pharmaceuticals
- Class
- Mechanism of Action Ribonuclease H inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 15 Mar 2012 Discontinued for HIV infections in United Kingdom (unspecified route)
- 12 Sep 2011 SuperGen is now called Astex Pharmaceuticals
- 20 Jul 2011 Astex Therapeutics has been acquired by SuperGen